General Information of Drug (ID: DMBY3T5)

Drug Name
FR-226928 Drug Info
Synonyms
FR-226928; CHEMBL350620; FR-226928 free base; BDBM50110416; 1-Naphthalenesulfonamide, N-(2-(4-((((6,7,8,9-tetrahydro-3-methoxy-5H-benzocyclohepten-6-yl)methyl)amino)methyl)-1-piperidinyl)ethyl)-; 765261-46-9; Naphthalene-1-sulfonic acid [2-(4-{[(3-methoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-6-ylmethyl)-amino]-methyl}-piperidin-1-yl)-ethyl]-amide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
10007341
CAS Number
CAS 765261-46-9
TTD Drug ID
DMBY3T5

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Preclinical Drug(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CGP71683A DMRYC08 Obesity 5B81 Discontinued in Phase 3 [2]
Velneperit DMROSHN Obesity 5B81 Discontinued in Phase 2 [3]
S-234462 DM80P4U Obesity 5B81 Discontinued in Phase 1 [3]
Axovan-3 DM1JN6A Eating disorder 6B82 Discontinued in Phase 1 [4]
FR-79620 DMXR287 Diabetic complication 5A2Y Preclinical [5]
GW-594884A DMHUD27 Obesity 5B81 Preclinical [5]
NPY5RA-972 DMXUCSN Obesity 5B81 Preclinical [5]
RWJ-49815 DMUGZMO Fungal infection 1F29-1F2F Terminated [4]
AR-129330 DMUSYKG Discovery agent N.A. Investigative [6]
Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)] DMKANOH Discovery agent N.A. Investigative [7]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuropeptide Y receptor type 5 (NPY5R) TTY6EWA NPY5R_HUMAN Inhibitor [1]

References

1 Novel potent antagonists of human neuropeptide Y Y5 receptors. Part 3: 7-methoxy-1-hydroxy-1-substituted tetraline derivatives. Bioorg Med Chem Lett. 2002 Mar 11;12(5):799-802.
2 Neuropeptide Y-induced enhancement of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 receptors. Neuropharmacology. 2007 May;52(6):1396-402.
3 Clinical pipeline report, company report or official report of Shionogi (2011).
4 Emerging drugs for eating disorder treatment. Expert Opin Emerg Drugs. 2006 May;11(2):315-36.
5 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
6 Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg Med Chem Lett. 2005 Sep 1;15(17):3853-6.
7 Bis(31/31')[[Cys(31), Nva(34)]NPY(27-36)-NH(2)]: a neuropeptide Y (NPY) Y(5) receptor selective agonist with a latent stimulatory effect on food intake in rats. Peptides. 2002 Aug;23(8):1485-90.